ResearcherNew York UniversityActive in the last 2 years

Camila Hidalgo Salinas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6279-3689; OpenAlex author ID A5108131982. Sources: OpenAlex.

Their work

Papers: 16 (first author 3, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 63

Papers, trials and grants by year

2023: 1 paper · 2024: 2 papers · 2025: 9 papers · 2026: 4 papers

Papers 16

Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776 ↗
Does ductal subtype predict outcomes after resection of IPMN-derived pancreatic cancer? An international multi-center retrospective study. First author DOI 10.1016/j.hpb.2026.08.011 ↗
Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… First author DOI 10.1016/j.surg.2026.110302 ↗
Implications of Neoadjuvant Therapy on Prognostic Factors in Pancreatic Ductal Adenocarcinoma: A Path Towards Personalized Prognostication. Co-author DOI 10.1097/sla.0000000000006660 ↗
Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024 ↗
Recognizing IPMN-derived pancreatic cancer as a specific entity requiring prospective clinical studies: a call for international collaboration. Co-author DOI 10.1093/jnci/djaf037 ↗
Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735 ↗
Defining and Predicting Early Recurrence for Optimal Treatment Strategies for Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: An Internation… Co-author DOI 10.1245/s10434-024-16649-z ↗
Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z ↗
ASO Author Reflections: Resected Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer: Early Recurrence and Patient-Tailored Management. Co-author DOI 10.1245/s10434-024-16810-8 ↗
Incidence and Outcomes of Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Compared with Tubular and Colloid Intraductal Papillary Mucinous N… First author DOI 10.1245/s10434-025-17810-y ↗
ASO Author Reflections: Old Truths, New Data: Intraductal Oncocytic Papillary Neoplasm-Derived Pancreatic Cancer Requires Continued Surveillance. Co-author DOI 10.1245/s10434-025-18007-z ↗
The Impact of Social Determinants of Health on Supportive and Palliative Care in Pancreatic Cancer Management: A Narrative Review. Co-author DOI 10.3390/cancers17193254 ↗
REDISCOVER guidelines for borderline-resectable and locally advanced pancreatic cancer: management algorithm, unanswered questions, and future perspectives. Co-author DOI 10.1007/s13304-024-01860-0 ↗
REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248 ↗
Oncological outcomes after pancreatoduodenectomy for pancreatic ductal adenocarcinoma in octogenarians: case-control study. Co-author DOI 10.1093/bjsopen/zrad053 ↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.